Bolt Biotherapeutics Stock Alpha and Beta Analysis

BOLT Stock  USD 0.49  0.02  3.92%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bolt Biotherapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bolt Biotherapeutics over a specified time horizon. Remember, high Bolt Biotherapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bolt Biotherapeutics' market risk premium analysis include:
Beta
(0.50)
Alpha
(0.18)
Risk
3.43
Sharpe Ratio
(0.12)
Expected Return
(0.40)
Please note that although Bolt Biotherapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Bolt Biotherapeutics did 0.18  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Bolt Biotherapeutics stock's relative risk over its benchmark. Bolt Biotherapeutics has a beta of 0.50  . As returns on the market increase, returns on owning Bolt Biotherapeutics are expected to decrease at a much lower rate. During the bear market, Bolt Biotherapeutics is likely to outperform the market. At this time, Bolt Biotherapeutics' Book Value Per Share is comparatively stable compared to the past year. Tangible Book Value Per Share is likely to gain to 2.82 in 2025, whereas Enterprise Value is likely to drop slightly above 56.5 M in 2025.

Enterprise Value

56.55 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Bolt Biotherapeutics Backtesting, Bolt Biotherapeutics Valuation, Bolt Biotherapeutics Correlation, Bolt Biotherapeutics Hype Analysis, Bolt Biotherapeutics Volatility, Bolt Biotherapeutics History and analyze Bolt Biotherapeutics Performance.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Bolt Biotherapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bolt Biotherapeutics market risk premium is the additional return an investor will receive from holding Bolt Biotherapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bolt Biotherapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bolt Biotherapeutics' performance over market.
α-0.18   β-0.5

Bolt Biotherapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bolt Biotherapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Bolt Biotherapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Bolt Biotherapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Bolt Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bolt Biotherapeutics shares will generate the highest return on investment. By understating and applying Bolt Biotherapeutics stock market price indicators, traders can identify Bolt Biotherapeutics position entry and exit signals to maximize returns.

Bolt Biotherapeutics Return and Market Media

The median price of Bolt Biotherapeutics for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 0.52 with a coefficient of variation of 8.34. The daily time series for the period is distributed with a sample standard deviation of 0.04, arithmetic mean of 0.54, and mean deviation of 0.04. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Bolt Biotherapeutics Stock Surges Amid Biotech Sector Movements
11/26/2024
2
Bolt Biotherapeutics stock hits 52-week low at 0.53 - Investing.com
12/12/2024
3
Disposition of 3792 shares by Vivo Capital Viii, Llc of Bolt Biotherapeutics at 0.92 subject to Rule 16b-3
12/23/2024
4
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024 - Marketscreener.com
12/31/2024
5
Colossal Joins Ranks Of SpaceX, OpenAI With 10.2 Billion Valuation
01/15/2025
6
Disposition of 27465 shares by Engleman Edgar of Bolt Biotherapeutics at 0.92 subject to Rule 16b-3
02/06/2025
7
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
02/11/2025

About Bolt Biotherapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bolt or other stocks. Alpha measures the amount that position in Bolt Biotherapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2022 2023 2024 2025 (projected)
Interest Debt Per Share0.610.530.480.32
Revenue Per Share0.150.210.190.2

Bolt Biotherapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Bolt Biotherapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bolt Biotherapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Bolt Biotherapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Bolt Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Bolt Biotherapeutics' management manipulating its earnings.
3rd of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Bolt Biotherapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.